Vita Reed covers healthcare, including health insurance, hospitals, medical devices and drug companies for the Orange County Business Journal. She can be reached at email@example.com.
HEALTHCARE: BK filing follows several loan defaults
Irvine-based AtheroNova Inc. is searching for a buyer willing to extend the cash-strapped startup’s existence as it reviews early data on its effort to develop drugs to fight atherosclerosis, or hardening of the arteries.
HEALTHCARE: New boss says search ‘unfolding’
Dr. Howard Federoff will soon take up some heavy lifting in his new job as the University of California-Irvine’s top healthcare executive.
Frees System to Invest In ‘Strategic Initiatives’
Fountain Valley-based MemorialCare Health System’s solid debt ratings were affirmed this month by New York City-based Fitch Ratings Inc.
Newport Beach-based Pacific Life Insurance Co. said today that Douglas Ingram, former president of Allergan Inc., has been elected to its board, effective May 1.
San Clemente-based medical device maker ReShape Medical Inc. has raised $2 million, according to a Securities and Exchange Commission filing.
David Pyott will remain chair of the Allergan Foundation, according to Actavis PLC, the Ireland-based drug maker that recently wrapped up its $72.5 billion buy of Irvine-based Allergan Inc.
Actavis PLC said today that it completed its acquisition of Irvine-based drugmaker Allergan Inc., currently valued at about $72.5 billion.
Irvine-based Edwards Lifesciences Corp.’s shares rose today on positive results from several studies of less-invasive heart valves.
HEALTHCARE: Consumer twist on medical device; ESPN spot
Irvine-based medical device maker Masimo Corp. will look to win a place in the world of big-time athletics as part of a marketing effort anchored by its sponsorship of the BNP Paribas Open tennis tournament in Indian Wells, which runs through this week.
HEALTHCARE: Still no word on job additions, cutbacks here
The “new” Allergan Inc. is set to move its medical dermatology business to Irvine as part of its specialty pharmaceutical base in the wake of Actavis PLC’s $70 billion-plus buy of the Botox maker.